{"name":"Relay Therapeutics","slug":"relay","ticker":"RLAY","exchange":"NASDAQ","domain":"relaytx.com","description":"Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercial","hq":"Cambridge, MA","founded":0,"employees":"193","ceo":"Sanjiv Patel","sector":"Precision Oncology","stockPrice":12.84,"stockChange":-0.38,"stockChangePercent":-2.87,"marketCap":"$2.5B","metrics":{"revenue":15355000,"revenueGrowth":-60.9,"grossMargin":0,"rdSpend":99862000,"netIncome":-276479000,"cash":642065024,"dividendYield":0,"peRatio":-7.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"RLT-352 patent cliff ($0.0B at risk)","drug":"RLT-352","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"RLT-189 patent cliff ($0.0B at risk)","drug":"RLT-189","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"RLAY Announces FDA Clearance of IND for RLT-352","summary":"Relay Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for RLT-352, a potential treatment for non-small cell lung cancer.","drugName":"RLT-352","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"RLAY Reports Third Quarter 2022 Financial Results","summary":"Relay Therapeutics reported its third quarter 2022 financial results, including a net loss of $34.6 million and a cash balance of $444.6 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"RLAY Announces Collaboration with Merck KGaA","summary":"Relay Therapeutics announced a collaboration with Merck KGaA to develop and commercialize RLT-189, a potential treatment for non-small cell lung cancer.","drugName":"RLT-189","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOZFpjeVdkUkIyNFZpR3NyY1JZRWIzY0xvZFBzbDZrSEllam1SV0RqT2drbkJVSHN5QVV5V0JUcGNjWTE5aHJqUGcyZ2RicERCdjA1bkM5V0dMcHlnZlU1dF9nLTVETUVoUXdPYklVQURXTnRQTk9STjdDSmdXTHlTY2tYZzdkX2hnZzFXSlpJWTZUTUp2QnpnTWJqUXAxYjE4cEVMakxFSjktZnI4ZFdPZnZ1ZG5YR2FNRFNtcGQzU1h4akRqbjNCeVI1NFUtRURRaXJkbmRqR29TaU8zYjFTN0VZam9Pek3SAewBQVVfeXFMTXJjb1hpYTdwamItY2VxNkhMcGlKQTJnWC1CUHk4dnVlMEYxblhJbk9hekxLUlAzT3o4akk4VDRfb3E1QzBOZ19iWF96clB5cWZxTF9kNVBWc1Qzd2J5ODNNYWNLVDRDZWNzTnE2RjVMYTVJME53Y3VaT0tHSy1oOWs0YnAzSTVVaThFbm9kaFExeXY3V2RfV0lPa3liNG1qU2taM2FkaFJvX1V6djhIRDdONnJ6cEpvWENXd0tYLXlIX3B0WXc0TmxsZ1REVGJhUEsyVnpoaU1SU2tMZXZTLUJKT0o4RG93bkliMXM?oc=5","date":"2026-04-06","type":"pipeline","source":"simplywall.st","summary":"Is Relay Therapeutics (RLAY) Building a Durable Precision-Medicine Platform with Its Zovegalisib Strategy? - simplywall.st","headline":"Is Relay Therapeutics (RLAY) Building a Durable Precision-Medicine Platform with Its Zovegalisib Strategy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPQXlaN3J5M0FwRUNUTjBOWkh6cWRuWjZnY3EyeEtHUEJWNHFKV1VVRmFfNEdGa2tmeHdRekE3LThMeUdndVY0LUdJTF90eW4xYjl3dGE0bTFyeHJOX3Vjak1EcmJVYTNQVk53aW9OaEF4VVZmQjYxOHVFMzFQazlSX0pmcFI0MHdhQ3ZZYnhnSzctX1lzRUU0WlRJVjJZSGY1bEU0eVdURm5CVFhRLWpmT2NDQTVybXZ5V1QzaldzQTgzaElWeVpUcmRkbjNQY2g5a3VzVg?oc=5","date":"2026-04-04","type":"pipeline","source":"AAII","summary":"Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII","headline":"Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQNFI1eGp0NExGV1h0dzlkTW9oWHBGRHlRYzdLcHpmOE10T0VFX0hLY0lQc29hb1lvOGlVaU9valpmZW5lRlNNS1E0d0lfcnlwM3NSMktWRl9pRnRyUVBxR0VKSll5R0NBZmFoNFFoVXBTNmxYNHJZVnN6UWV0NFpBNGM5VF9pU29ON1kzdXZ0LVdIYnc5THVpRDh2cmlxZi1acWhPY3JXZzFKTEhZeTBiQWszS0xZV2dxM0xPbU8yS2hWQlMtM0hrOUExRHhUTDF4N1BuUVVGU25BTFJhWXczaHhzRS1JYVHSAewBQVVfeXFMUEt1eWZmRXlyVENHQklYUFpNdFFCNmpWVV9TdXZveFJUVzJ1Tm4yMjk3dFVTOUdvVGdiZ2J5ODBrRXJTSmxZMmtaTERjWlY4bXdIbGdISXVZTWZWcVlQekZEeE8tdHFXM2Q3VUZlU2RUVGNvek9HRHJCeFZLcmZDWUhFMEl6T1IxdzJZWU05ZGYzbUJ3dGZpQll5MGtUbGstbUVCeEdZOHlvYzlyVF9uZ1htUTFZVmpjS0tjLWdkR01JZjRkSExrYnZoMHh0RlFDNF82WHlNUjhEWlpFS21TZlF2WThRSklvbEc2SFY?oc=5","date":"2026-03-30","type":"regulatory","source":"simplywall.st","summary":"Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status - simplywall.st","headline":"Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"earnings","source":"simplywall.st","summary":"Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative - simplywall.st","headline":"Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOOFkzYnZha2RJZTdWTDlSbWxQMGYyeE01SUdsODNPcTFkYmJTcWcxOXBIV2VSUUFKWEVXMmdlLTRyY1M0bXpOUl9CZ0diUVRuSHBuLXFCTVpIUWN3Ymp1ZUdBazhiQ1VRQ2ZnOXppVGNYZ2V6RUlpaWlWNDBUel9sSzJYZGZLSGZqdW5FX2Utd0pwWVlILURxQ2cxTEhuM1BOZlN1MVVR?oc=5","date":"2026-02-03","type":"regulatory","source":"The Pharma Letter","summary":"Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter","headline":"Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPRC1PRHl2d0x5bnUtS09vV1dfQmRYU3BzVjhMSjQya0NfSkxDSzJqa0FwVWxUQ2lMaHpDOWNNSmo0Y21QNjBIbkhYVTlNcEpoaWdLN2JidS1fcmZObmk3V1ZMN0JMM0ZZQS1wd2FqLWJydVFNaXlHSmxXT2Y3TWNTVnBTcVVVbHdtR0NlcGwwZGhJTmpYQnhQZVd1emF1eGh4ek9penRSeEcyMXQ3WTNMYUxR?oc=5","date":"2025-11-06","type":"earnings","source":"investingnews.com","summary":"Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates - investingnews.com","headline":"Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNOWlfRkNtRlRUWnBEcUdFTjdtbkREdUNNTXUxNDhWU3Y1dHFfTE5Cdk1MRWs5MWlySWRpTkdRYWh4SFhwT1FRemtGLVM0VFBSNmtvX0lvNzczTGZJMUxSWGtlN0xKMWxxOEpOWUo0ZmVfeDVpQVF6OFZVdUk5WEQ5Ync3QjNBTzk2dWlybnp6YVN2MElFYVFsb1BObExFcnpNWjJxQmJ0YUpFMkhzcGVWMXpxZklWRUdwS3RwNXlPZTVnUHBLUERlUWNBY2ZTUQ?oc=5","date":"2025-09-18","type":"trial","source":"Investing.com","summary":"Relay Therapeutics’ SWOT analysis: AI-driven biotech stock faces pivotal phase - Investing.com","headline":"Relay Therapeutics’ SWOT analysis: AI-driven biotech stock faces pivotal phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQdVg0MVlwQlo1X3dSamVEVHY5aUtleGZPWll5alA2X1V6YkJwcDN0bHJTeThibDF5U25hYWg3SU4xdnVVcTRMSkQ4ZDY1Y2dyN1hyd05nM09PNG9PM1FKaC1kdDBoV0ZHdVJncDdpaW54bHRiMUs4UEZiZXA5QVgzQWphZndhZUU0RmZfYXlWSTl3Zm5aZHJjTF8zRkZ5RkRpR0xCeDExRGcwWFdacDE0MFktcDBWRllCSkE?oc=5","date":"2025-07-25","type":"pipeline","source":"TradingView","summary":"RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - TradingView","headline":"RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOR1dLMEFydmhBWHhjWXRPZTdBYTJCaHd0ZE51WTRPcldUdnZkTUNMWloxVlpKSGV4a1duZmNEcDN2V19yYUxGSlFJblJmcTRCdEZSVFVOc3ZSekJ2NmFZVERnemJVQ19GWklhRlZRY2dhV08yXzhCbkkwZkg5UGFOUUtDNndhdmd6NldwZTFlNUs5TEh4TDJj?oc=5","date":"2025-07-16","type":"deal","source":"Yahoo Finance","summary":"Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - Yahoo Finance","headline":"Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOSVQzMkNRLW1EQmlPY0c4bjZLelpDNVBOZTZ6dTYtc1ZmX1ZYMDUwS3o2b3MzWUx2M2l3Uk96NXFmSGYyS3pXN1NDajliUnQzU1NxcUtQNENRZHRNQ3djLVZkSlA5U3lrU2ttYXcyX21UZHJYQXZjcXhFYW14dkxjNjhYUjE5enFpQmVaOS1lQUpWWXA5Y3VtUUxSdnNtSENycFE3aGt5U01lYkFVcWZBVE5tdXRDZXFHMU85aUhwWi1hVDc2LXVmSXVFejd6LU84a1pVZkVQTGluZXNZS2MwRFVJLWY4bmtrSkE?oc=5","date":"2025-07-02","type":"pipeline","source":"The Globe and Mail","summary":"Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - The Globe and Mail","headline":"Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?","sentiment":"neutral"}],"patents":[{"drugName":"RLT-352","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"RLT-189","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["AstraZeneca","Merck & Co.","Bristol Myers Squibb"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":15355000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":15355000,"period":"2025-12-31"},{"value":10007000,"period":"2024-12-31"},{"value":10007000,"period":"2024-12-31"},{"value":25546000,"period":"2023-12-31"},{"value":25546000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":99862000,"rdSpendHistory":[{"period":"2025-12-31","value":261383000},{"period":"2024-12-31","value":319089000},{"period":"2023-12-31","value":330018000},{"period":"2022-12-31","value":246355000}],"sgaSpend":56710000,"operatingIncome":-302738000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-302738000},{"period":"2024-12-31","value":-385674000},{"period":"2023-12-31","value":-379422000},{"period":"2022-12-31","value":-310952000}],"netIncome":-276479000,"netIncomeHistory":[{"period":"2025-12-31","value":-276479000},{"period":"2024-12-31","value":-337708000},{"period":"2023-12-31","value":-341973000},{"period":"2022-12-31","value":-290509000}],"eps":-2.36,"epsHistory":[{"period":"2024-12-31","value":-2.36},{"period":"2023-12-31","value":-2.79},{"period":"2022-12-31","value":-2.59},{"period":"2021-12-31","value":-3.82}],"cash":84018000,"cashHistory":[{"period":"2025-12-31","value":84018000},{"period":"2024-12-31","value":124287000},{"period":"2023-12-31","value":143736000},{"period":"2022-12-31","value":151794000}],"totalAssets":621331000,"totalLiabilities":54271000,"totalDebt":32458000,"equity":567060000,"operatingCashflow":-235455000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-235455000},{"period":"2024-12-31","value":-249107000},{"period":"2023-12-31","value":-300316000},{"period":"2022-12-31","value":-229490000}],"capex":-410000,"capexHistory":[{"period":"2025-12-31","value":-410000},{"period":"2024-12-31","value":-2018000},{"period":"2023-12-31","value":-4126000},{"period":"2022-12-31","value":-9062000}],"freeCashflow":-235865000,"dividendsPaid":null,"buybacks":null,"employees":193,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":12215000,"ebit":-60630000,"ebitda":-60031000,"period":"2025-12-31","revenue":7000000,"epsBasic":-0.32,"netIncome":-54890000,"rdExpense":55415000,"epsDiluted":-0.32,"grossProfit":null,"operatingIncome":-60630000},{"sga":12129000,"ebit":-80391000,"ebitda":-79643000,"period":"2025-09-30","revenue":0,"epsBasic":-0.43,"netIncome":-74149000,"rdExpense":68262000,"epsDiluted":-0.43,"grossProfit":null,"operatingIncome":-80391000},{"sga":13627000,"ebit":-76847000,"ebitda":-75845000,"period":"2025-06-30","revenue":677000,"epsBasic":-0.41,"netIncome":-70375000,"rdExpense":63897000,"epsDiluted":-0.41,"grossProfit":null,"operatingIncome":-76847000},{"sga":18739000,"ebit":-84869000,"ebitda":-83661000,"period":"2025-03-31","revenue":7679000,"epsBasic":-0.46,"netIncome":-77065000,"rdExpense":73809000,"epsDiluted":-0.46,"grossProfit":null,"operatingIncome":-84869000},{"sga":16904000,"ebit":-84979000,"ebitda":-83645000,"period":"2024-12-31","revenue":0,"epsBasic":-0.45,"netIncome":-76004000,"rdExpense":68075000,"epsDiluted":-0.45,"grossProfit":null,"operatingIncome":-84979000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":12.84,"previousClose":13.22,"fiftyTwoWeekHigh":17.32,"fiftyTwoWeekLow":2.67,"fiftyTwoWeekRange":"2.67 - 17.32","fiftyDayAverage":12.44,"twoHundredDayAverage":7.99,"beta":1.75,"enterpriseValue":1922271104,"forwardPE":-7.4,"priceToBook":3.94,"priceToSales":230.42,"enterpriseToRevenue":180.06,"enterpriseToEbitda":-6.55,"pegRatio":0,"ebitda":-293606016,"ebitdaMargin":0,"freeCashflow":-121180872,"operatingCashflow":-213356992,"totalDebt":31567000,"debtToEquity":4.9,"currentRatio":22.13,"returnOnAssets":-24.7,"returnOnEquity":-40,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":21,"targetHighPrice":25,"targetLowPrice":18,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.6,"institutionHeldPercent":91.9,"sharesOutstanding":191586165,"floatShares":115913462,"sharesShort":27410626,"shortRatio":7.58,"shortPercentOfFloat":14.3,"epsTrailing":-1.56,"epsForward":-1.72,"revenuePerShare":0.06,"bookValue":3.26,"officers":[{"age":51,"name":"Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS","title":"CEO, President & Director"},{"age":65,"name":"Dr. Mark  Murcko Ph.D.","title":"Founder & Independent Director"},{"age":48,"name":"Mr. Thomas  Catinazzo","title":"Chief Financial Officer"},{"age":43,"name":"Mr. Peter  Rahmer","title":"Chief Corporate Development Officer"},{"age":53,"name":"Dr. Donald A. Bergstrom M.D., Ph.D.","title":"President of Research & Development"},{"age":null,"name":"Ms. Dorothee  Kern Ph.D.","title":"Founder"},{"age":74,"name":"Dr. David Elliot Shaw Ph.D.","title":"Founder"},{"age":null,"name":"Dr. Matthew P. Jacobson Ph.D.","title":"Founder"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.relaytx.com","phone":"617 370 8837"}}